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Abstract 
 
Single missense mutations in the F8 gene encoding the coagulation protein factor VIII 
(FVIII) give rise predominantly to non-severe hemophilia A. Despite only a single amino 
acid sequence difference between the replacement, therapeutic FVIII (tFVIII) and the 
patient’s endogenous FVIII, tFVIII may still be perceived as foreign by the recipient’s 
immune system and trigger an immune response (inhibitor). Inhibitor formation is a life-
long risk for non-severe hemophilia A patients treated with tFVIII, but remains difficult 
to predict.  The aim of this study was to understand whether fortuitous, primary sequence 
cross-matches between tFVIII and proteins in the human proteome are the reason why 
certain F8 mutations are not associated with inhibitor formation. We predicted which 
tFVIII differences are potentially perceived as foreign by helper T cells – a necessary 
precursor to inhibitor development – and then scanned potentially immunogenic peptides 
against more than 100,000 proteins in the proteome. As there are hundreds of disease-
causing F8 missense mutations and the Human Leucocyte Antigen gene complex 
governing peptide presentation to helper T cells is highly polymorphic, these calculations 
pose a huge combinatorial challenge that we addressed computationally. We identify that 
cross-matches between tFVIII and the human proteome are commonplace and have a 
profound impact on the predicted risk of inhibitor development. Our results emphasize 
the importance of knowing both the F8 missense mutation and the Human Leucocyte 
Antigen alleles of a patient with missense mutation hemophilia A if his underlying risk of 
inhibitor development is to be estimated.  
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Introduction 
 
All severities of hemophilia A (HA) are at risk of an alloimmune response (inhibitor 
formation) against infused, therapeutic FVIII (tFVIII) concentrate.  It is well recognized 
that the more disruptive the F8 mutation, the more severe the hemophilia and the more 
likely it is that inhibitors will arise.1  Consequently, severe HA has been the priority for 
inhibitor-related research, surveillance and intervention over the past decades.2–5 
However, it is also clear that only a single amino acid difference between an endogenous 
F8 genotype and the wild-type tFVIII sequence is sufficient to induce an immune 
response that results in clinically relevant inhibitors6–8 and that this risk is life-long in the 
context of non-severe HA.8   
 
HA caused by a missense mutation is typically associated with a less severe bleeding 
phenotype than HA caused by incomplete F8 transcripts. In contrast to severe HA, boys 
and men living with non-severe HA are more likely to remain hospital dependent for on-
demand tFVIII administration throughout their lives in the event of injury or surgery.  
The treatment burden for this group is surprisingly high, with 44% of a large London 
cohort being reported to have received some hemostatic treatment in a 2-year observation 
window, 79% of whom received tFVIII concentrate.9 Consequently, inhibitor 
surveillance in non-severe HA requires adult treaters to be ever vigilant.8  In contrast to 
the systematic inhibitor screening in early tFVIII exposures for severe HA,5 inhibitor 
screening in the non-severe HA setting is currently more reactive and sporadic,9 but 
recognized to be of increasing importance given the ageing population of those living 
with non-severe HA.10  Inhibitor occurrence in non-severe hemophilia A can be 
devastating, with neutralization of infused FVIII concentrate and potential cross-
reactivity with endogenous FVIII.  This cross-reactivity occurs in at least 50% of 
identified cases11 and results in loss of a patient’s previous non-severe FVIII activity 
baseline level (FVIII:C) resulting in a worsening bleeding phenotype, often in latter 
decades of life.8 This results in increased bleed rates and an increased risk of premature 
mortality.12  In this context, the early detection of inhibitor occurrence – or, better still, 
the ability to reliably predict an individual’s risk of developing inhibitors before any have 
formed – has the potential to influence subsequent clinical decisions in ways that 
substantially improve patient outcomes.  
 
The T-cell dependency of inhibitor generation is well described, with confirmed tFVIII-
specific CD4+ T-cell responses13–15 and immunoglobulin class switching.16 CD4+ T-cell 
activation depends on their interaction with “foreign” peptides – in this case, tFVIII-
derived peptides spanning the location of the endogenous F8 missense mutation – 
presented by Major Histocompatibility Complex (MHC) class II molecules. However, not 
all such foreign peptides are perceived to be immunologically different from self and, if 
the difference is undetected, there is presumed negligible risk of an immune response. 
There are two key mechanisms at work here. Firstly, not all peptides are capable of 
binding to an individual’s repertoire of MHC molecules and are therefore never presented 
to T cells. Secondly, not all binding peptides are distinguishable from self-peptides bound 
to the same MHC molecules; in such cases, T cells that are capable of binding to these 
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MHC:peptide complexes are expected to have been removed from the T-cell repertoire 
by self-tolerance mechanisms.17  
 
What is unclear, however, is whether an understanding of MHC presentation and self-
tolerance can enable us to make useful predictions about the inhibitor risk of patients with 
missense mutation HA – for example, by accurately predicting whether individual 
patients have a negligible risk of developing inhibitors. The aim of this study is to 
directly address that point. Given that MHC molecules are encoded by genes that are 
among the most polymorphic in the human genome, and there are several hundred 
disease-causing F8 missense mutations, the first aim of this study was to predict inhibitor 
risk based on an analysis of tFVIII peptide presentation by MHC molecules. Such an 
investigation poses a huge combinatorial challenge – one that is arguably impractical to 
address using purely in vitro techniques. Building on the approach developed in an earlier 
study that we undertook using a much smaller dataset,18 we analyzed MHC:peptide 
complexes associated with 25 common HLA class II alleles and 956 distinct F8 missense 
mutations,  requiring over 4 million peptide-HLA isoform combinations to be evaluated.  
 
However, this preliminary analysis did not take into account the possibility that fortuitous 
cross-matches between tFVIII-derived peptides and peptides at other locations – both 
within the FVIII protein sequence itself, and more generally to other proteins in the 
human proteome – may play a protective role by ensuring that T cells capable of 
triggering an immune response have been removed from the repertoire by self-tolerance 
mechanisms. This includes, but is far from limited to, the well-described homology 
between FVIII and factor V.19 Such human proteome cross-matching is the main focus of 
this study. Here we demonstrate that cross-matches between tFVIII and other parts of the 
proteome are commonplace and have a profound impact on the predicted inhibitor risk 
for individuals living with non-severe hemophilia A.   
 
 
Methods 
 
Novel peptide-MHC surfaces 
 
In previous work, we developed a methodology for predicting which patients with non-
severe HA are at risk of developing antibodies against tFVIII.18 Specifically, we 
predicted which F8 missense mutation/HLA isoform combinations would present novel 
peptide-MHC (pMHC) surfaces to CD4+ T cells, taking into account the reasonable 
assumption that T cells capable of binding to pMHC surfaces that are formed by 
endogenous FVIII peptides and presented by the same MHC molecules would have been 
removed from the T-cell repertoire by central tolerance mechanisms. Novelty arises when 
a tFVIII-derived peptide is an MHC-binder (most are not) and either i) the equivalent 
endogenous FVIII-derived peptide is a non-binder (this may occur if the missense 
mutation is at an MHC-facing, peptide-anchoring position, as residues at such positions 
anchor the peptide to the MHC molecule) or ii) the relevant amino-acid difference is at a 
TCR-facing position (Figure 1A).  
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Our earlier work focused exclusively on the location of the hemophilia-causing F8 
missense mutation and HLA-DR presentation. Here we extend our analysis to include 
HLA-DP and -DQ presentation and, crucially, to take into account the possibility of 
fortuitous peptide cross-matches to other locations – both within FVIII itself, and more 
generally within other proteins in the human proteome (Figure 1B).  
 
Peptide-MHC binding prediction 
 
We used the in silico tool NetMHCII20 to predict the strength with which a given peptide 
binds to an MHC molecule – specifically, the portable version of NetMHCII 2.2 
(Technical University of Denmark, http://www.cbs.dtu.dk/services/NetMHCII/). If a 
peptide is predicted to bind with a 50% inhibitory concentration (IC50) of <1000 nmol/L 
– the conventional threshold used to indicate that peptide-MHC class II binding is of 
biological significance21  – it is a candidate for forming a novel pMHC surface. Deciding 
whether a given combination of tFVIII peptide and MHC molecule forms a novel pMHC 
surface in comparison to the corresponding endogenous FVIII-derived  peptide requires 
the considerations outlined in Figure 1 to be made, given: a) knowledge of the positions 
of the MHC anchoring pockets for the chosen HLA isoform (generally these are at 
positions 1, 4, 6 and 9,); and b) the binding register of the peptide (predicted by 
NetMHCII), which specifies the stretch of 9 consecutive amino-acid residues that form 
the preferred binding core within the MHC groove. Predictions were made for 25 
common HLA-DR, -DP and -DQ isoforms with estimated worldwide population 
coverages of >70%, >90% and >80% respectively22 using UniProt23 FVIII sequence 
P00451.  
 
For the full set of 25 HLA class II alleles considered for this research, over 4 million 
peptide-HLA isoforms combinations were evaluated in order to identify the combinations 
that are predicted to form a novel pMHC surface – plus a similar order of additional 
evaluations necessary to identify potential cross-matches to the human proteome. A 
detailed breakdown of the calculations performed is given in Online Supplementary 
Table S1.  
 
Scanning the human proteome for cross-matches  
  
Our preliminary risk assessment focused exclusively on the location of the disease-
causing F8 missense mutation – that is, we assessed whether one or more peptides would 
be perceived as foreign, given the binding properties and side-chain orientations of both 
tFVIII and endogenous FVIII peptides spanning the location of the missense mutation 
(Figure 1A). The innovative hypothesis explored here is that some pMHC surfaces that 
were identified as risk-associated by this preliminary approach may not be novel within 
the broader context of the whole human proteome.  
  
For this research, we compared pMHC surfaces formed by tFVIII peptides spanning the 
location of the F8 missense mutation with those formed by peptides from the human 
proteome. Following research showing that the “maximal representation of the 
‘immunological self’”17 is made available for tolerance induction in the thymus, we used 
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the complete human proteome from Ensembl24 containing over 100,000 proteins, 
including alternative isoforms that have an associated protein product.  
 
As previously, we confined our analysis to 15-mers, this being the most common peptide 
length chosen for MHC class II binding experiments. The canonical proteome was sub-
divided into all possible 9-mers. The resultant dataset consists of nearly 38 million 9-
mers of which more than 11 million are non-identical. 
 
A summary of the computational pipeline used to identify novel pMHC surfaces is shown 
in Figure 2. 
 
Statistical analysis 
 
We evaluated the accuracy of our method using F8 mutation data downloaded from the 
large source of F8 mutation data in the public domain (The European Association for 
Haemophilia and Allied Disorders. The Factor VIII Gene (F8) Variant Database. 
http://www.factorviii-db.org. Accessed November 26 2016). The dataset contained 956 
distinct F8 missense mutations at 605 different loci from 3,243 individuals. Ninety of the 
missense mutations were associated with at least one reported case of inhibitor formation, 
with a total of 160 individuals (prevalence 4.9%) listed as having inhibitors.  
 
We tested the null hypothesis that our predicted rate and the database reported rate of 
inhibitor formation are independent. In the absence of patient HLA-typing information, 
we predicted whether a patient with a given missense mutation has a risk of inhibitor 
formation based on the combined predictions for our chosen set of 25 common HLA 
class II isoforms. We evaluated different IC50 binding thresholds for tFVIII peptides, on 
the grounds that binding strength is likely to be an important factor in inhibitor risk.25 
However, when considering peptide-MHC binding in the context of self-tolerance 
prediction (e.g. the binding potential of proteome cross-matches), we maintained a 
binding threshold of 1000 nM. For a given tFVIII-peptide binding threshold, a patient’s 
predicted risk of inhibitor formation was deemed to fall within one of the following three 
categories: “predicted low/negligible risk”, “predicted at risk”, or “unknown risk”. A 
patient was deemed to be at low/negligible risk if no novel pMHC surfaces were 
predicted to be formed with any of the 25 HLA isoforms. A patient was deemed to be “at 
risk” if novel pMHC surfaces were predicted to be formed by all, or all but one, of the 
HLA isoforms encoded by at least one HLA gene complex – HLA-DRB1, HLA-
DRB3/4/5, HLA-DP, and/or HLA-DQ isoforms. (Here the “all, or all but one” condition 
was designed to rule out the possibility that the patient was a heterozygous individual 
having a risk-free combination of common HLA isoforms, i.e. two or more 
low/negligible risk isoforms per gene complex.) The inhibitor risk for patients in neither 
of the preceding categories was considered “unknown”. Patients with unknown inhibitor 
risk were omitted from the statistical test. 
 
The statistical test was undertaken using the two-tailed Fisher’s exact test implemented in 
the R statistical programming language. The Fisher’s exact test is necessary because the 
sample size and background inhibitor rate are both relatively low; in such circumstances, 
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the calculation of exact P values is important. Following standard convention, a P value 
of <0.05 was used to define statistical significance. 
 
 
 
Results 
 
An example of proteome cross-matching 
 
Arg593Cys (R593C) (R612C using Human Genome Variation Society numbering) is a 
relatively common F8 missense mutation that has been identified as being associated 
with an “increased” risk of inhibitor formation – for example, 12/106 (11.3%) of R593C 
individuals within the INSIGHT cohort have been reported as having an inhibitor.8 
Taking the common HLA-DR allele HLA-DRB1*01:01 as an example, our analysis of 
predicted inhibitor risk proceeded as follows. 
 
We began by using NetMHCII20 to predict whether any of the tFVIII 15-mers spanning 
position 593 are binders. Several such 15-mers were predicted to bind to the MHC 
molecule associated with HLA-DRB1*01:01, and some had binding cores that span 
position R593. There were two such cores – IQRFLPNPA and YLTENIQRF – both of 
which were associated with multiple binding peptides, as shown in Figure 3A. 
 
The next step assessed whether either of these cores was associated with predicted pMHC 
surface novelty compared to their respective endogenous counterparts. Both of the 
endogenous cores – IQCFLPNPA and YLTENIQCF respectively (with a Cys (C) in place 
of the Arg (R) of the equivalent tFVIII peptides) – were associated with predicted binding 
15-mers. Hence the question of predicted novelty hinged on the position of R593 within 
the 9-mer: whether at a position involved in MHC-binding (and hence invisible to a 
TCR), or at a TCR-facing position? As the binding pockets in the MHC groove for HLA-
DRB1*01:01 are at positions 1, 4, 6 and 9, both IQRFLPNPA (with R593 at TCR-facing 
position 3) and YLTENIQRF (with R593 at TCR-facing position 8) are associated with 
the formation of pMHC surfaces that are novel in comparison to those formed by 
endogenous FVIII, as shown in Figure 3B. 
 
Based on the preceding analysis alone, we would predict that a patient with the R593C 
mutation and HLA-DR allele HLA-DRB1*01:01 would be at risk of developing 
inhibitors. However, a tFVIII-derived pMHC surface that is novel with respect to an 
individual’s endogenous FVIII may not be novel in the wider context of his proteome. To 
evaluate this possibility of a proteome cross-match that reduces the risk of inhibitor 
development, we searched for a pattern for each of the 9-mer cores matching at T-cell 
facing positions 2, 3, 5, 7 and 8. For IQRFLPNPA and YLTENIQRF these patterns are 
XQRXLXNPX and XLTXNXQRX respectively, where the letter X matches any amino-
acid type. These patterns were scanned against a library containing all 11,272,502 unique 
9-mers from the human proteome. In this case, the pattern XQRXLXNPX matched the 9-
mer FQRELNNPL in human tubulin polyglutamylase (UniProt25 Q6ZT98), and pattern 
XLTXNXQRX matched both the 9-mer GLTENSQRD in dystrobrevin binding protein 1 
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(dysbindin) (UniProt D6RJC6) and the 9-mer ELTKNAQRA in the uncharacterized 
human protein C2orf48 (UniProt Q96LS8), as shown in Figure 4A.  
 
The final step was to check whether a given cross-matching, proteome-derived 9-mer 
occurred as a binding core for HLA-DRB1*01:01, as only then would we hypothesize 
tolerance. In this case, NetMHCII predicted that both FQRELNNPL in tubulin 
polyglutamylase and ELTKNAQRA in C2orf48 form cores within 15-mers with a 
predicted IC50 <1000 nmol/L, as shown in Figure 4B. Hence, we ultimately predicted that 
the F8 missense mutation/HLA allele combination R593C/HLA-DRB1*01:01 confers 
no, or negligible, risk of inhibitor formation owing to fortuitous cross-matches to peptides 
in the human proteome. 
 
Proteome cross-matches and inhibitor risk stratification 
 
In terms of individual combinations of F8 missense mutation and HLA-DR/DP/DQ 
isoforms, the impact of proteome cross-matches on predicted risk is shown in a 
comprehensive heat map (Online Supplementary Figure S1), with a subset of 
combinations shown in Figure 5. Each individual F8 missense mutation/HLA isoform 
combination is shown as a single square. An analysis of the full set of data indicates that 
the percentage of F8 missense mutation/HLA isoform combinations associated with 
predicted inhibitor risk falls appreciably when proteome cross-matches are taken into 
account: from 49% to 31% with a binding threshold of 1000 nM; and from 37% to 21% 
with a binding threshold of 500 nM.  
 
These predictions strongly suggest that the risk of inhibitor formation is largely HLA-
dependent and, in most cases, cannot be reliably predicted from knowledge of the F8 
genotype alone. The proportion of reported F8 missense mutations that we predict to be 
risk-associated varies considerably between different HLA isoforms. For example, with a 
binding threshold of 1000 nM, it ranges between 21% (HLA-DQA1*03:01-DQB1*03:02 
and HLA-DQA1*04:01-DQB1*04:02) to 86% (HLA-DRB1*01:01) without proteome 
cross-matches, and between 13% (HLA-DQA1*04:01-DQB1*04:02) and 48% (HLA-
DRB1*01:01) with proteome cross-matches. Values for all 25 HLA isoforms and 
multiple binding thresholds are given in Online Supplementary Table S2. The number of 
F8 missense mutations associated with no, or negligible, predicted risk (black columns in 
the heatmap) is only 69 out of 956 (7%). 
 
We consider any (human) protein that, in effect, contributes to a reduction in predicted 
inhibitor risk for one or more F8 missense mutation/HLA isoform combinations to be 
“protective”. Of the 20,300 proteins in the human proteome, 4,605 are protective. The 
protein that affords the most protection is factor V, which is recognized as having high 
homology with FVIII.19
 The most protective proteins identified in our analysis are listed 
in Table 1. It is notable that FVIII and all the top entries in Table 1 (coagulation factor V, 
hephaestin-like protein 1, ceruloplasmin, and hephaestin) have copper-binding sites.  
 
 
Evaluation of risk prediction accuracy 
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Given the paucity of published data specifying the HLA profiles of patients with 
missense mutation HA, we have based the evaluation of how accurate our approach is at 
predicting potential risk on data in the Factor VIII Gene (F8) Variant Database, focusing 
on F8 missense mutations that we predict to have low or negligible risk with any 
common HLA isoform.  
 
Arguably the most important performance indicator for our method is the number of false 
negatives: are there individuals with missense mutation hemophilia A and with data in 
the Factor VIII Gene Variant Database that we predict to have a zero, or negligible, 
inhibitor risk but have, in fact, developed inhibitors? The results in Table 2 for our 
chosen set of 25 HLA alleles show that the number of false negatives (column 3) is very 
low with conservative cut-offs for peptide-MHC binding affinity. The number of patients 
predicted to have a zero, or negligible risk of inhibitor development is considerably 
higher when cross-matches to the proteome are taken into account, but the false negative 
rate remains comparatively low; these factors taken together contribute to the higher 
prevalence of statistically significant P values with proteome cross-matching.    
 
 
Discussion  
 
In this paper, we highlight the potential value of an in silico predictive model of HLA 
class II antigen presentation as the basis for identifying patients with missense mutation 
hemophilia A who are at risk of developing inhibitors against tFVIII. Our pipeline 
incorporates a novel strategy that we term proteome scanning – the identification of 
fortuitous cross-matches between potentially antigenic tFVIII peptides and peptides 
arising elsewhere within the human proteome. Such cross-matching peptides are the basis 
for protection against inhibitor development because of presumed T-cell tolerance 
mechanisms. Here we focused on the surfaces formed by tFVIII peptides that span the 
locations of known disease-causing F8 missense mutations and are predicted to bind to 
the MHC molecules for 25 common HLA class II alleles. Given a conservative binding 
threshold of 1000 nM, the number of F8 missense mutation/HLA isoform combinations 
associated with a risk of developing inhibitors was predicted to fall by more than a third – 
from 49% to 31% – when cross-matches to the proteome are taken into account. These 
results were shown to be statistically significant with a dataset of missense mutation HA 
patients derived from the Factor VIII Gene Variant Database.  
  
Although our proteome scanning approach reduces the number of patients predicted to be 
at risk of developing inhibitors, that number remains higher than, albeit closer to, the 
number of patients that have – at least to date – developed inhibitors. This is inevitable 
for a model based entirely on a consideration of MHC/TCR interactions, as a range of 
downstream factors may militate against inhibitor development. These include: the 
absence of sufficient T cells capable of binding to a given pMHC surface for reasons 
other than self-tolerance; the lack of co-stimulatory signalling; or the level of exposure to 
tFVIII being below the threshold necessary for inhibitor formation (only cursory 
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information about a patient’s degree of exposure to tFVIII is available in the Factor VIII 
Gene Variant Database database).  
 
There are a number of ways in which this analysis could be refined. Firstly, we took no 
account of potential F8 genotype mismatches between tFVIII products (derived from 
common F8 genotypes H1 and H2 that differ only in the B domain) and rare genotypes 
H3-8, such as the M2238V found in approximately 23% of black people.26 Nor did we 
consider the antigenic impact of different linkers used in B-domain modified tFVIII 
products. Secondly, proteome scanning was performed against a single reference 
proteome. It is likely that additional cross-matches will be found if allelic variants are 
taken into account, adding further to the potential advantages of personalized risk 
assessment. Scanning against an individual’s own proteome would be the optimal 
predictive strategy. The impact of proteome variability will be assessed in future work 
using data from IGSR: The International Genome Sample Resource.27 
 
There are several more challenging issues. Our model of peptide-MHC binding is 
imperfect, for example: we do not take into account the impact of cathepsin cleavage on 
the availability of FVIII peptides for MHC class II binding (there are no established 
computational methods for predicting cleavage by cathepsins, and different sets of 
cathepsins occur in different professional antigen presenting cells28); peptide differences 
at anchoring positions,29 or outside the binding core,30 are known to affect the formation 
of pMHC surface in specific cases (but the prevalence of such effects is poorly 
understood); and a given TCR may not be in contact with all TCR-facing residues (but 
the binding angle and register of individual TCRs is currently unpredictable).31 
  
Validating the accuracy of inhibitor risk prediction for patients with non-severe HA is 
also particularly problematic. In practice, the current, clinical gold standard for inhibitor 
detection is a functional, clotting-based Bethesda assay.  However, heat treatment 
modifications in the presence of residual FVIII:C (i.e. non-severe HA) are often omitted, 
resulting in reduced sensitivity of detection.32 More importantly, a purely “functional” 
clotting assay does not detect the totality of antibody responses against a protein 
therapeutic. The absence of a more “neutral” screening assay (e.g. ELISA based) to pick 
up any anti-tFVIII antibody response first, and subsequently for the functional assay 
(Bethesda) to determine its inhibitory potential and clinical relevance, compromises our 
knowledge of the totality of anti-tFVIII responses in our patient cohorts.  It is also evident 
that in contrast to severe HA, screening practice for antibody responses in non-severe HA 
are often opportunistic and passive, further reducing the likelihood of detecting the 
totality of anti-tFVIII antibody responses by missing the optimal immunological windows 
for screening after tFVIII exposure.9 Given the life-long risk of inhibitor formation in 
non-severe HA, we have concerns that true negatives (i.e. patients confirmed to have a 
zero risk of inhibitor development) are impossible to identify in a non-severe HA clinical 
study, even when factors such as age and exposure are taken into account. 
 
Notwithstanding these limitations, this study provides compelling evidence of the 
importance of HLA class II genotyping for analyzing the inhibitor risk of patients with 
missense mutation HA. Moreover, we have demonstrated that an innovative 
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computational pipeline incorporating proteome scanning predicts that a large proportion 
of F8 missense mutation/HLA isoform combinations afford a negligible risk of inhibitor 
development, with a low error rate when evaluated using the largest available dataset of 
HA patients with F8 missense mutations and conservative MHC binding thresholds. This 
represents an important step forward, as it closes part of the gap between 
predicted/potential inhibitor risk and observed inhibitor rates. These insights may 
ultimately contribute to the design of future clinical studies (with HLA typing of 
missense mutation HA patients) that are of direct translational relevance. 
 
Acknowledgements 
 
D.P.H. received funding from the British Society of Haematology. 
 
References 
  1.  Schwaab R, Brackmann HH, Meyer C, et al. Haemophilia A: mutation type 
determines risk of inhibitor formation. Thromb Haemost. 1995;74(6):1402–1406. 
  2.  Gouw SC, van der Bom JG, Ljung R, et al. Factor VIII products and inhibitor 
development in severe hemophilia A. N Engl J Med. 2013;368(3):231–239. 
  3.  Gouw SC, van den Berg HM, Fischer K, et al. Intensity of factor VIII treatment and 
inhibitor development in children with severe hemophilia A: the RODIN study. 
Blood. 2013;121(20):4046–4055. 
  4.  Collins PW, Palmer BP, Chalmers EA, et al. Factor VIII brand and the incidence of 
factor VIII inhibitors in previously untreated UK children with severe hemophilia A, 
2000-2011. Blood. 2014;124(23):3389–3397. 
  5.  Collins PW, Chalmers E, Hart DP, et al. Diagnosis and treatment of factor VIII and 
IX inhibitors in congenital haemophilia: (4th edition). UK Haemophilia Centre 
Doctors Organization. Br J Haematol. 2013;160(2):153–170. 
  6.  Fischer K, Iorio A, Lassila R, et al. Inhibitor development in non-severe haemophilia 
across Europe. Thromb Haemost. 2015;114(4):670–675. 
  7.  Hay CR. Factor VIII inhibitors in mild and moderate-severity haemophilia A. 
Haemophilia. 1998;4(4):558–563. 
  8.  Eckhardt CL, van Velzen AS, Peters M, et al. Factor VIII gene (F8) mutation and 
risk of inhibitor development in nonsevere hemophilia A. Blood.                                       
2013;122(11):1954–1962. 
  9.  Batty P, Austin SK, Khair K, et al. Treatment burden, haemostatic strategies and real 
world inhibitor screening practice in non-severe haemophilia A. Br J Haematol. 
2017;176(5):796–804. 
10.  Hvas A-M, Poulsen LH. Inhibitor screening in non-severe haemophilia patients; a 
major challenge. Br J Haematol. 2017;176(5):683–685. 
HUMAN PROTEOME AND HEMOPHILIA A INHIBITOR RISK 
 12
11.  van Velzen AS, Eckhardt CL, Hart DP, et al. Inhibitors in nonsevere haemophilia A: 
outcome and eradication strategies. Thromb Haemost. 2015;114(1):46–55. 
12.  van Velzen AS, Eckhardt CL, Streefkerk N, et al. The incidence and treatment of 
bleeding episodes in non-severe haemophilia A patients with inhibitors. Thromb 
Haemost. 2016;115(3):543–550. 
13.  James EA, Van Haren SD, Ettinger RA, et al. T-cell responses in two unrelated 
hemophilia A inhibitor subjects include an epitope at the factor VIII R593C missense 
site: T-cell responses to a FVIII missense site in hemophilia A. J Thromb Haemost. 
2011;9(4):689–699. 
14.  Ettinger RA, James EA, Kwok WW, Thompson AR, Pratt KP. HLA-DR-restricted 
T-cell responses to factor VIII epitopes in a mild haemophilia A family with 
missense substitution A2201P. Haemophilia. 2010;16(102):44–55. 
15.  James EA, Kwok WW, Ettinger RA, Thompson AR, Pratt KP. T-cell responses over 
time in a mild hemophilia A inhibitor subject: epitope identification and transient 
immunogenicity of the corresponding self-peptide. J Thromb Haemost. 
2007;5(12):2399–2407. 
16.  Whelan SFJ, Hofbauer CJ, Horling FM, et al. Distinct characteristics of antibody 
responses against factor VIII in healthy individuals and in different cohorts of 
hemophilia A patients. Blood. 2013;121(6):1039–1048. 
17.  Derbinski J, Kyewski B. How thymic antigen presenting cells sample the body’s 
self-antigens. Curr Opin Immunol. 2010;22(5):592–600. 
18.  Shepherd AJ, Skelton S, Sansom CE, Gomez K, Moss DS, Hart DP. A large-scale 
computational study of inhibitor risk in non-severe haemophilia A. Br J Haematol. 
2015;168(3):413–420. 
19.  Davidson CJ, Hirt RP, Lal K, et al. Molecular evolution of the vertebrate blood 
coagulation network. Thromb Haemost. 2003;89(3):420–428. 
20.  Nielsen M, Lund O. NN-align. An artificial neural network-based alignment 
algorithm for MHC class II peptide binding prediction. BMC Bioinformatics. 
2009;10(1):296. 
21.  Southwood S, Sidney J, Kondo A, et al. Several common HLA-DR types share 
largely overlapping peptide binding repertoires. J Immunol. 1998;160(7):3363–3373. 
22.  Wang P, Sidney J, Kim Y, et al. Peptide binding predictions for HLA DR, DP and 
DQ molecules. BMC Bioinformatics. 2010;11(1):568. 
23.  UniProt Consortium. Reorganizing the protein space at the Universal Protein 
Resource (UniProt). Nucleic Acids Res. 2012;40(D1):D71-75. 
D.P. Hart et al. 
 13
24.  Yates A, Akanni W, Amode MR, et al. Ensembl 2016. Nucleic Acids Res. 
2016;44(D1):D710-716. 
25.  Lazarski CA, Chaves FA, Jenks SA, et al. The kinetic stability of MHC class 
II:peptide complexes is a key parameter that dictates immunodominance. Immunity. 
2005;23(1):29–40. 
26.  Viel KR, Ameri A, Abshire TC, et al. Inhibitors of factor VIII in black patients with 
hemophilia. N Engl J Med. 2009;360(16):1618–1627. 
27.  1000 Genomes Project Consortium, Auton A, Brooks LD, et al. A global reference 
for human genetic variation. Nature. 2015;526(7571):68–74. 
28.  Hsing LC, Rudensky AY. The lysosomal cysteine proteases in MHC class II antigen 
presentation. Immunol Rev. 2005;207(1):229–241. 
29.  Kersh GJ, Miley MJ, Nelson CA, et al. Structural and functional consequences of 
altering a peptide MHC anchor residue. J Immunol. 2001;166(5):3345–3354. 
30.  Deng L, Langley RJ, Brown PH, et al. Structural basis for the recognition of mutant 
self by a tumor-specific, MHC class II-restricted T cell receptor. Nat Immunol. 
2007;8(4):398–408. 
31.  Rudolph MG, Stanfield RL, Wilson IA. How TCRs bind MHCs, peptides, and 
coreceptors. Annu Rev Immunol. 2006;24:419–466. 
32.  Jennings IA, Kitchen D, Kitchen S, et al. Variation in Practice for FVIII and FIX 
Inhibitor Investigations - Results from a UK NEQAS (Blood Coagulation) and UK 
HCDO Multicentre Exercise. Res Pract Thromb Haemost. 2017;1(S1):525. 
 
 
  
HUMAN PROTEOME AND HEMOPHILIA A INHIBITOR RISK 
 14
Tables 
 
Table 1. Human proteins that afford the greatest proteome cross-match protection 
 
UniProt ID Protein name Protected peptide count 
P12259 Coagulation factor V  640 
Q6MZM0 Hephaestin-like protein 1 457 
P00450 Ceruloplasmin 437 
Q9BQS7 Hephaestin 389 
P00451 Coagulation factor VIII [match to different, but 
homologous, location within the protein] 
251 
O75445 Usherin 150 
Q14585 Zinc finger protein 345 142 
Q14587 Zinc finger protein 268 134 
Q96M86 Dynein heavy chain domain-containing protein 83 
O00154 Cytosolic acyl coenzyme A thioester hydrolase 76 
Q7LBC6 Lysine-specific demethylase 3B 75 
Q9UKF2 Disintegrin and metalloproteinase domain-
containing protein 30 
75 
Q9Y2P0 Zinc finger protein 835 74 
P10745 Retinol-binding protein 3 73 
Q5T5N4 Uncharacterized protein C6orf118  67 
The protected peptide count for a given combination of human protein p, F8 missense mutation m and HLA 
isoform h is incremented by 1 every time a peptide in tFVIII that spans the location of m is a) associated 
with a predicted risk of inhibitor development for h prior to considering cross-matches to the human 
proteome, and b) cross-matches to a peptide in p that is a predicted binder for h. Hence a peptide that cross-
matches to multiple binding peptides at different locations within p will be counted multiple times. The 
final count for p is the aggregate of individual counts for all F8 missense mutation/HLA isoform 
combinations considered in this study.   
D.P. Hart et al. 
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Table 2. Evaluation of zero/negligible inhibitor risk prediction with and without proteome scanning  
 
IC50 binding 
threshold 
(nmol/L) 
Patients predicted to have 
zero/negligible risk 
Patients predicted to have an 
inhibitor risk 
P 
No inhibitors Inhibitors Inhibitors No inhibitors 
Without proteome scanning 
1000 28 1 116 1344 0.72 
500 49 3 92 985 0.62 
300 122 3 84 787 5.84e-04 
200 179 9 76 660 0.02 
100 362 20 37 338 0.02 
50 593 36 31 228 2.01e-03 
With proteome scanning 
1000 103 4 80 622 0.02 
500 157 7 65 339 4.50e-05 
300 322 14 57 261 1.14e-08 
200 465 26 53 232 1.07e-08 
100 777 42 23 133 6.57e-05 
50 1,114 66 22 115 3.72e-05 
P values were calculated by applying Fisher’s exact test to patients from the Factor VIII Gene Variant 
Database falling into the following categories: predicted to have zero/negligible risk, observed to have no 
inhibitors (column 2); predicted to have zero/negligible risk, observed to have inhibitors (column 3); 
predicted to have inhibitor risk, observed to have inhibitors (column 4); and predicted to have inhibitor risk, 
observed to have no inhibitors (column 5). P values <0.05 are deemed statistically significant and are 
shown in italics. 
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Figure Legends 
 
Figure 1. Schematic diagram showing how side-chain differences may, or may not, lead to novel 
peptide-MHC surfaces. A) If a tFVIII peptide spanning the location of the F8 missense mutation is a non-
binder, it poses no risk of forming a novel pMHC surface capable of inducing an immune response. 
Otherwise, one needs to consider the position of the F8 missense mutation within the MHC groove of the 
tFVIII peptide and the corresponding endogenous peptide. For most HLA class II isoforms, positions 1,4 6 
and 9 are MHC-facing, and positions 2, 3, 5, 7 and 8 are TCR-facing. Where the F8 missense mutation is at 
a downward, MHC-facing position (top row of A, denoted by a diamond), there are 2 scenarios: both 
tFVIII and endogenous peptides are binders, implying no risk; or the tFVIII peptide is a binder and the 
endogenous peptide is a non-binder, implying a potential risk. Where the F8 missense mutation is at an 
upward, TCR-facing position (bottom row of A, denoted by a diamond) and both peptides are binders, there 
is a potential risk. B) Where a tFVIII peptide is associated with a potential risk according to the preceding 
assessment, a peptide from elsewhere in the human proteome that a) has the same TCR-facing residues and 
b) is a binder, will militate against this risk, as no novel pMHC surface will be formed. 
 
Fig 2. Flowchart for the assessment of human proteome cross-matching and missense mutation HA 
inhibitor risk. Shown is the process by which the presence, or otherwise, of a novel peptide-MHC surface 
is determined given a specific combination of endogenous F8 missense mutation and HLA isoform. 
 
Fig 3. A peptide-MHC binding and novel surface example: Arg593Cys for HLA-DRB1*0101. (A) 
NetMHCII predicts there are binding tFVIII 15-mers that have two cores – IQRFLPNPA and YLTENIQRF 
– containing Arg593 (R593). (B) These two cores form pMHC surfaces that are novel compared to the 
equivalent surfaces for endogenous FVIII.  
 
Fig 4. A proteome cross-matching example: Arg593Cys for HLA-DRB1*0101. This example concerns 
the two tFVIII binding cores from Figure 3, IQRFLPNPA and YLTENIQRF. (A) Both cores cross-match 
to 9-mers from proteins in the human proteome at TCR-facing positions 2, 3, 5, 7 and 9. (B) Both of the 
matched 9-mers (one each from tubulin polyglutamylase and C2orf48, but none from dysbindin) are 
predicted by NetMHCII to form binding cores within 15-mers derived from these proteins. Hence, we 
conclude that the F8 missense mutation/HLA isoform combination Arg593Cys/HLA-DRB1*0101 is 
associated with negligible risk of inhibitor formation. 
 
 
Figure 5. MHC-binding strengths of F8 peptides predicted to form novel pMHC surfaces with and 
without proteome scanning.  Heatmap showing the predicted occurrence of novel pMHC surfaces and 
binding strengths for 25 HLA-DR/DP/DQ isoforms (y axis) covering the first 50 missense mutations in the 
Factor VIII Gene (F8) Variant Database (x axis). Black and grey squares indicate F8 missense 
mutation/HLA isoform combinations that are not predicted to form a novel pMHC surface. Otherwise the 
temperature color scale indicates the predicted binding strength of the strongest binding peptide with a 
novel pMHC surface for each remaining F8 missense mutation/HLA isoform combination. The full 
heatmap for all missense F8 mutations is given in Online Supplementary Figure S1. (A) MHC-binding 
strengths of F8 peptides predicted to form novel pMHC surfaces (colored squares), or not (black squares), 
without proteome scanning. (B) MHC-binding strengths of F8 peptides predicted to form novel pMHC 
surfaces with proteome scanning. Grey squares indicate F8 missense mutation/HLA isoform combinations 
that are no longer predicted to form a novel pMHC surface after cross-matches to the proteome are taken 
into account. 
  
 





Supplemental Information 
 
Supplemental Table S1. Breakdown of calculations required to identify novel 
peptide-MHC surfaces.  
 
Description Count Calculation Total 
 
Step 1: calculations required for a single residue 
15-mers spanning residue 15  15 
Positions 15-mer can bind to MHC 7 15 × 7 105 
HLA alleles 25 105 × 25 2,625 
 
Step 2: calculations required for endogenous FVIII (using total from step 1) 
Reported F8 missense mutations 956 2,625 × 956 2,509,500 
 
Step 3: calculations required for tFVIII (using total from step 1) 
Locations associated with F8 
mutations 
605 2,625 × 605 1,588,125 
 
Step 4: summation  
Sum totals from step 2 and step 3  2,509,500 + 1,588,125 4,097,625 
    
Step 5: proteome scanning    
Two different types of calculation are required: a) matching 9-mer cores of risk-associated peptides 
(from step 4) to proteome 9-mers (see Figure 4A); and b) calculating the MHC binding cores and 
binding strengths of matched peptides (see Figure 4B). We do not keep track of the exact number 
of calculations performed, so here we estimate the lower bounds.    
a) Proteome matching: 
Risk-associated peptides ≫12,189   
Non-identical proteome 9-mers 11,272,502 12,189 × 11,272,502  137,400,526,878 
b) MHC binding:     
F8 mutation/HLA allele combinations 
with reduced risk after scanning 
4,302   
Rough estimate of ratio of non-
binders to binders 
10 4,302 × 10  43,020 
Note that the number of calculations at step 2 is higher than the number at step 3 because a single 
location may be associated with more than one reported missense mutation, e.g. K48E, K48T and 
K48N.  
 
  
Supplemental Table S2. Percentage of risk-associated F8 missense mutations for 
different HLA alleles, before and after proteome scanning 
 
HLA allele 
risk (%) with 
1000 nM threshold 
risk (%) with 
500 nM threshold 
before after before after 
DRB1*01:01 86 48 78 41 
DRB1*03:01 34 25 24 16 
DRB1*04:01 62 38 47 25 
DRB1*04:04 66 38 53 26 
DRB1*04:05 60 35 49 28 
DRB1*07:01 70 46 60 39 
DRB1*08:02 36 23 16 10 
DRB1*09:01 66 41 50 25 
DRB1*11:01 58 37 43 24 
DRB1*13:02 34 25 26 16 
DRB1*15:01 64 36 49 25 
DRB3*01:01 35 25 24 17 
DRB4*01:01 60 33 39 16 
DRB5*01:01 58 40 48 31 
DPA1*01-DPB1*04:01 41 27 33 23 
DPA1*01:03-DPB1*02:01 46 29 36 21 
DPA1*02:01-DPB1*01:01 59 34 47 25 
DPA1*02:01-DPB1*05:01 30 18 17 8 
DPA1*03:01-DPB1*04:02 52 33 41 22 
DQA1*01:01-DQB1*05:01 27 21 19 15 
DQA1*01:02-DQB1*06:02 54 34 36 20 
DQA1*03:01-DQB1*03:02 21 15 10 6 
DQA1*04:01-DQB1*04:02 21 13 11 6 
DQA1*05:01-DQB1*02:01 36 18 24 12 
DQA1*05:01-DQB1*03:01 58 32 40 20 
  
Supplemental Figure S1. MHC-binding strengths of F8 peptides predicted to form 
novel pMHC surfaces with and without proteome scanning.   
 
Heatmap showing the predicted occurrence of novel pMHC surfaces and binding strengths for 25 HLA-
DR/DP/DQ alleles (y axis) covering the complete set of missense mutations in the Factor VIII Gene 
(F8) Variant Database (x axis). Black and grey squares indicate F8 missense mutation/HLA allele 
combinations that are not predicted to form a novel pMHC surface. Otherwise the temperature color 
scale indicates the predicted binding strength of the strongest binding peptide with a novel pMHC 
surface for each remaining F8 missense mutation/HLA allele combination. (A) MHC-binding strengths 
of F8 peptides predicted to form novel pMHC surfaces without proteome scanning. (B) MHC-binding 
strengths of F8 peptides predicted to form novel pMHC surfaces with proteome scanning. Grey squares 
indicate F8 missense mutation/HLA allele combinations that are no longer predicted to form a novel 
pMHC surface after cross-matches to the proteome are taken into account. 
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